Primrose Bio and Intravacc have entered into a strategic partnership to strengthen the development & supply of conjugate vaccines under which the third-party developers of conjugate vaccines gain access to a solution for vaccine conjugation, manufacturing, and supply
The collaboration will leverage Primrose Bio’s ultra-pure production, supply chain management & regulatory support for PeliCRM197, a component required for conjugate vaccine development
Intravacc will provide its technical knowledge, advanced facilities, expertise in antigen conjugation process development, scale-up & GMP production of conjugate vaccines to the collaboration
Ref: Intravacc | Image: Intravacc
Related News:- Merck’s Vaxneuvance (pneumococcal 15-valent conjugate vaccine) Receives the US FDA’s Approval for the Prevention of Invasive Pneumococcal Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
